1. Scrip
  2. >>Focus On Asia
  3. >>China

Chinese ADC, RNA Therapy Developers Lead May/June Fundraising

 
• By Dexter Jie Yan

Emerging companies including Bliss Biopharmaceutical, Coherent Biopharma and WestGene Biopharma lifted China biotech funding from May to mid-June.

funding
Antibody-drug conjugates and RNA therapies come to fore as promising assets in China • Source: Shutterstock

Although financings of over $100m have become something of a rarity for Chinese biotechs, venture capital and private equity firms, as well as pharma companies, have recently made sizeable cash injections into the hot segments of antibody-drug conjugates (ADCs) and RNA therapies.

ADC developer Bliss Biopharmaceutical (Hangzhou) Co., Ltd revealed on 6 June its Japanese partner Eisai Co., Ltd. had...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Biokin/BMS’s Iza-bren Hits First Phase III OS Endpoint, Albeit In China

 
• By Dexter Jie Yan

Sichuan Biokin Pharmaceutical's BMS-partnered bispecific antibody-drug conjugate iza-bren had met both endpoints of PFS and OS in a China-only Phase III trial for the second-line treatment of esophageal squamous cell carcinoma.

Ascletis Flaunts Promise Of Its Co-Formulation Of Amylin/GLP-1/GIPR Agonists In Obesity

 
• By Xu Hu

Ascletis’ peptide co-formulation of ASC36 and ASC35 outperformed the co-formulation of Eli Lilly’s eloralintide and tirzepatide as well as eloralintide alone in a rat model, boosting the China-based firm’s confidence in upcoming clinical outcomes.

Investors Shower Chinese In Vivo CAR-T Biotechs With Quick Cash

 
• By Dexter Jie Yan

Byterna, Starna, Vivacta and DeliNova ride surging investor sentiment on in vivo CAR-T assets to secure venture funding.

Beijing Mabworks Scores World-First Phase III Win In Membranous Nephropathy

 
• By Dexter Jie Yan

In a world-first, Beijing Mabworks has scored a Phase III clinical win for its novel anti-CD20 antibody in the treatment of primary membranous nephropathy. However, multiple global contenders including Roche are threatening to come from behind in the race.

More from Focus On Asia

Hanmi Secures North America Beachhead Via Aptose Acquisition

 
• By Jung Won Shin

Hanmi is acquiring the Toronto-based biotech, Aptose, following positive early data of its lead asset tuspetinib in AML. The deal also gives Hanmi a strategic foothold in North America and marks another oncology-focused acquisition by a Korean pharma firm.

Asia Deal Watch: GSK To Collaborate With LTZ On Myeloid Cell Engagers

 
• By Joseph Haas, Xu Hu, Lisa Takagi, Jung Won Shin, and Sushmita Panda

Plus deals involving Adagene/Third Arc, Celltrion/TRiOar, Celltrion/Kaigene, ImmunoScape/Cue, Laekna/Qilu, Lilly/ABL, Lilly/Sanegene, Sanyou/ZJ Bio-Tech, TransThera/Neurocrine, Qyuns/Roche, Otsuka/4D Molecular, IASO/GC Cell, Chugai/Renalys, Henlius/Forlong and Teijin/Elevara.

Biokin/BMS’s Iza-bren Hits First Phase III OS Endpoint, Albeit In China

 
• By Dexter Jie Yan

Sichuan Biokin Pharmaceutical's BMS-partnered bispecific antibody-drug conjugate iza-bren had met both endpoints of PFS and OS in a China-only Phase III trial for the second-line treatment of esophageal squamous cell carcinoma.